SG11202003743SA - Compounds as mpges-1 inhibitors - Google Patents
Compounds as mpges-1 inhibitorsInfo
- Publication number
- SG11202003743SA SG11202003743SA SG11202003743SA SG11202003743SA SG11202003743SA SG 11202003743S A SG11202003743S A SG 11202003743SA SG 11202003743S A SG11202003743S A SG 11202003743SA SG 11202003743S A SG11202003743S A SG 11202003743SA SG 11202003743S A SG11202003743S A SG 11202003743SA
- Authority
- SG
- Singapore
- Prior art keywords
- mpges
- inhibitors
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203033 | 2017-11-22 | ||
| PCT/EP2018/082146 WO2019101826A1 (en) | 2017-11-22 | 2018-11-22 | Compounds as mpges-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003743SA true SG11202003743SA (en) | 2020-06-29 |
Family
ID=60450482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003743SA SG11202003743SA (en) | 2017-11-22 | 2018-11-22 | Compounds as mpges-1 inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11672787B2 (enExample) |
| EP (1) | EP3713564B1 (enExample) |
| JP (2) | JP7754623B2 (enExample) |
| KR (2) | KR20250109241A (enExample) |
| CN (1) | CN111417393A (enExample) |
| AU (1) | AU2018371153B2 (enExample) |
| BR (1) | BR112020010089A2 (enExample) |
| CA (1) | CA3079483A1 (enExample) |
| ES (1) | ES2963906T3 (enExample) |
| IL (1) | IL274821A (enExample) |
| MX (1) | MX2020005238A (enExample) |
| MY (1) | MY207603A (enExample) |
| PL (1) | PL3713564T3 (enExample) |
| SG (1) | SG11202003743SA (enExample) |
| WO (1) | WO2019101826A1 (enExample) |
| ZA (1) | ZA202002103B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3058033A1 (en) * | 2017-04-05 | 2018-10-11 | Khondrion Ip B.V. | Treatment of mitochondrial diseases |
| NL2024431B1 (en) * | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
| NL2025730B1 (en) * | 2020-06-02 | 2022-01-20 | Sulfateq Bv | Compounds for treatment of sepsis |
| WO2025242849A1 (en) * | 2024-05-24 | 2025-11-27 | Khondrion Ip B.V. | Chromanyl derivatives for use in the treatment of bone disorders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02250831A (ja) * | 1989-03-23 | 1990-10-08 | Kuraray Co Ltd | ３，４―ジヒドロ―２ｈ―ベンゾピラン誘導体及びそれを有効成分とする抗消化性潰瘍剤 |
| WO2006063466A1 (en) | 2004-12-17 | 2006-06-22 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors |
| US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
| DE102006053475A1 (de) | 2006-11-14 | 2008-06-19 | Eberhard-Karls-Universität Tübingen | Zubereitungen zur Hemmung der Prostaglandin E2 Synthese |
| DE102006058450A1 (de) | 2006-12-12 | 2008-06-19 | Eberhard-Karls-Universität Tübingen | Zubereitungen zur Hemmung der Prostaglandin E2 Synthese |
| SI3456707T1 (sl) * | 2007-11-06 | 2020-10-30 | Ptc Therapeutics, Inc. | Derivati 4-(P-kuinonil)-2-hidroksibutanamida za zdravljenje mitohondrijske bolezni |
| WO2009130242A1 (en) | 2008-04-23 | 2009-10-29 | Novasaid Ab | Low molecular weight derivatives and use thereof in treatment of prostaglandin e synthase related diseases |
| DE102008027331A1 (de) | 2008-06-07 | 2009-12-10 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2010127152A2 (en) | 2009-04-29 | 2010-11-04 | Irm Llc | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors |
| WO2011023812A1 (en) | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
| WO2012110860A1 (en) | 2011-02-17 | 2012-08-23 | Glenmark Pharmaceuticals S.A. | TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| WO2013038308A1 (en) | 2011-09-15 | 2013-03-21 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS |
| WO2013072825A1 (en) | 2011-11-16 | 2013-05-23 | Glenmark Pharmaceuticals S.A. | Phtalazinone derivatives as mpegs -1 inhibitors |
| AR089939A1 (es) | 2012-02-09 | 2014-10-01 | Glenmark Pharmaceuticals Sa | COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1 |
| WO2013153535A1 (en) | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| US9388156B2 (en) * | 2012-07-12 | 2016-07-12 | Khondiron IP B.V. | Chromanyl derivatives for treating mitochondrial disease |
| ES2622190T5 (es) | 2012-07-12 | 2020-04-23 | Khondrion Ip B V | Derivados de cromanilo para tratar una enfermedad mitocondrial |
| NL2010010C2 (en) | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
| ES2838625T3 (es) | 2014-04-14 | 2021-07-02 | Shanghai hengrui pharmaceutical co ltd | Derivados de amida y sales farmacéuticamente aceptables de los mismos, su método de preparación y aplicación médica de los mismos |
| NL2013012B1 (en) * | 2014-06-17 | 2016-07-05 | Sulfateq Bv | Compounds for the treatment of chronic obstructive airway diseases. |
| AU2016268975B2 (en) * | 2015-05-22 | 2021-08-12 | Sulfateq B.V. | Compound for the prophylaxis or treatment of organ damage |
| WO2017060432A1 (en) * | 2015-10-08 | 2017-04-13 | Khondrion Ip B.V. | Novel compounds for treating mitochondrial disease |
| CA3058033A1 (en) * | 2017-04-05 | 2018-10-11 | Khondrion Ip B.V. | Treatment of mitochondrial diseases |
| AU2018371152B2 (en) * | 2017-11-22 | 2024-02-08 | Khondrion Ip B.V. | Novel compounds for use in treating depression and migraine |
-
2018
- 2018-11-22 US US16/765,169 patent/US11672787B2/en active Active
- 2018-11-22 AU AU2018371153A patent/AU2018371153B2/en active Active
- 2018-11-22 MY MYPI2020002221A patent/MY207603A/en unknown
- 2018-11-22 KR KR1020257022058A patent/KR20250109241A/ko active Pending
- 2018-11-22 MX MX2020005238A patent/MX2020005238A/es unknown
- 2018-11-22 CA CA3079483A patent/CA3079483A1/en active Pending
- 2018-11-22 KR KR1020207017202A patent/KR20200090818A/ko not_active Ceased
- 2018-11-22 ES ES18808288T patent/ES2963906T3/es active Active
- 2018-11-22 JP JP2020526121A patent/JP7754623B2/ja active Active
- 2018-11-22 CN CN201880075549.3A patent/CN111417393A/zh active Pending
- 2018-11-22 PL PL18808288.7T patent/PL3713564T3/pl unknown
- 2018-11-22 EP EP18808288.7A patent/EP3713564B1/en active Active
- 2018-11-22 BR BR112020010089-7A patent/BR112020010089A2/pt unknown
- 2018-11-22 WO PCT/EP2018/082146 patent/WO2019101826A1/en not_active Ceased
- 2018-11-22 SG SG11202003743SA patent/SG11202003743SA/en unknown
-
2020
- 2020-05-04 ZA ZA2020/02103A patent/ZA202002103B/en unknown
- 2020-05-20 IL IL274821A patent/IL274821A/en unknown
-
2023
- 2023-09-11 JP JP2023147032A patent/JP2024009799A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020010089A2 (pt) | 2020-11-03 |
| EP3713564C0 (en) | 2023-11-15 |
| KR20200090818A (ko) | 2020-07-29 |
| ES2963906T3 (es) | 2024-04-03 |
| PL3713564T3 (pl) | 2024-04-08 |
| RU2020120235A (ru) | 2021-12-22 |
| MY207603A (en) | 2025-03-06 |
| AU2018371153B2 (en) | 2023-07-13 |
| MX2020005238A (es) | 2020-08-24 |
| CA3079483A1 (en) | 2019-05-31 |
| AU2018371153A1 (en) | 2020-06-04 |
| EP3713564B1 (en) | 2023-11-15 |
| JP7754623B2 (ja) | 2025-10-15 |
| CN111417393A (zh) | 2020-07-14 |
| ZA202002103B (en) | 2023-12-20 |
| KR20250109241A (ko) | 2025-07-16 |
| US20200345706A1 (en) | 2020-11-05 |
| WO2019101826A1 (en) | 2019-05-31 |
| JP2024009799A (ja) | 2024-01-23 |
| US11672787B2 (en) | 2023-06-13 |
| IL274821A (en) | 2020-07-30 |
| EP3713564A1 (en) | 2020-09-30 |
| JP2021504307A (ja) | 2021-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201708456D0 (en) | Senolytic compounds | |
| GB201700814D0 (en) | Compounds | |
| PT3371190T (pt) | Compostos heterocíclicos como inibidores de pi3k-gamma | |
| SMT202200345T1 (it) | Composti utili come inibitori di ret | |
| GB201704327D0 (en) | Compounds | |
| GB201704325D0 (en) | Compounds | |
| IL274821A (en) | Substances that inhibit MPGES-1 and their uses | |
| PT3643718T (pt) | Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1 | |
| GB201707938D0 (en) | Compounds | |
| GB201707856D0 (en) | Compounds | |
| GB201706162D0 (en) | Compounds | |
| GB201702221D0 (en) | Compounds | |
| ZA201907792B (en) | Heterocyclic compound | |
| GB201707852D0 (en) | Compounds | |
| GB201703282D0 (en) | Compounds | |
| ZA201907793B (en) | Heterocyclic compound | |
| GB201720145D0 (en) | Inhibitor compounds | |
| GB201708507D0 (en) | Inhibitor compounds | |
| GB201708502D0 (en) | Inhibitor compounds | |
| GB201708510D0 (en) | Inhibitor compounds | |
| GB201705968D0 (en) | Inhibitor compounds | |
| GB201709642D0 (en) | Compounds | |
| GB201708846D0 (en) | Compounds | |
| GB201708845D0 (en) | Compounds | |
| GB201708848D0 (en) | Compounds |